Doravirine, Rifapentine and Isoniazid Interaction

Inclusion Criteria: 1. Healthy male or female between 18-60 years old at the time of screening. 2. Have a Body Mass Index (BMI) \> 19 and \< 33. 3. Weigh \> 45 kg but \< 120 kg. 4. Non-smoker (tobacco or electronic cigarettes). 5. Negative QuantiFERON-TB Gold at screening. 6. Subjects who agree to abstain from alcohol consumption throughout the duration of the study. 7. Female subjects of childbearing potential must demonstrate a urine beta-hCG consistent with non-pregnancy at the time of the screening visit and agree to the use (and/or have their partner use) of an acceptable method of birth-control at initial screening, during the time of the trial and until two weeks after the last dose of drug following the last treatment period. 8. Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study. Exclusion Criteria: 1. History of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, dermatologic, psychiatric abnormalities or neurological (including stroke and chronic seizure) diseases. 2. \>500 mL blood or plasma donation in the 6 weeks prior to study start 3. Known anaphylactic or severe systemic reactions to any components of doravirine, rifapentine, isoniazid or pyridoxine. 4. Positive HIV, Hepatitis B or Hepatitis C virus. Evidence of prior Hepatitis B infection and immunity is not exclusionary. 5. Latent or active tuberculosis infection. Documented prior fully treated latent tuberculosis is not exclusionary. 6. Females who are postpartum \< 12 months. 7. Current drug or alcohol abuse. 8. Received study drug in another study within 4 weeks or within 5 half-lives, which ever occurring first, before first anticipated dose of study drug in this study. 9. Unable to refrain from use of over-the-counter, prescription (unless determined appropriate by the investigator), herbal or natural products, vitamins or supplements, or grapefruit juice/grapefruit products. 10. Any clinical significant findings on lab, ECG or physical exam at screening.